Alfredo Falcone


Ontology type: schema:Person     


Person Info

NAME

Alfredo

SURNAME

Falcone

Publications in SciGraph latest 50 shown

  • 2019-01-28 Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib in THE PHARMACOGENOMICS JOURNAL
  • 2018-09 Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer in THE PHARMACOGENOMICS JOURNAL
  • 2018-08 Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients in INVESTIGATIONAL NEW DRUGS
  • 2018-04 Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials in BRITISH JOURNAL OF CANCER
  • 2018-03-20 PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC in BRITISH JOURNAL OF CANCER
  • 2017-12 TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group in BMC CANCER
  • 2017-12 Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months in EXPERIMENTAL HEMATOLOGY & ONCOLOGY
  • 2017-12 Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer in SCIENTIFIC REPORTS
  • 2017-07-25 The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab in BRITISH JOURNAL OF CANCER
  • 2017-06 Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer in THE PHARMACOGENOMICS JOURNAL
  • 2017-02 First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2017-01 Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2017-01 Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care in SUPPORTIVE CARE IN CANCER
  • 2016-12 Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients in INVESTIGATIONAL NEW DRUGS
  • 2016-07 Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients in SCIENTIFIC REPORTS
  • 2016-05 Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’ in BRITISH JOURNAL OF CANCER
  • 2016-04 Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases in SCIENTIFIC REPORTS
  • 2016-01 Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2015-12 Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer in BMC CANCER
  • 2015-12 Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2015-10 First-line chemotherapy for mCRC—a review and evidence-based algorithm in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2015-09 A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs in JOURNAL OF GASTROINTESTINAL CANCER
  • 2015-07 Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients in NATURE MEDICINE
  • 2015-07 Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients in NATURE MEDICINE
  • 2015-06 BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection in BRITISH JOURNAL OF CANCER
  • 2015-02 Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer in THE PHARMACOGENOMICS JOURNAL
  • 2014-09 EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan in TARGETED ONCOLOGY
  • 2014-08 Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients in THE PHARMACOGENOMICS JOURNAL
  • 2014-04 Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer in BRITISH JOURNAL OF CANCER
  • 2014-04 Dedicated supportive care team at the oncology unit: a model of simultaneous care for cancer patients in SUPPORTIVE CARE IN CANCER
  • 2014-02 A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy in EPMA JOURNAL
  • 2014 The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients in METRONOMIC CHEMOTHERAPY
  • 2013-12 Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab’ in BRITISH JOURNAL OF CANCER
  • 2013-08 VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide in BRITISH JOURNAL OF CANCER
  • 2013-06 Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab in BRITISH JOURNAL OF CANCER
  • 2013-03 Supportive care and not only palliative care in the route of cancer patients in SUPPORTIVE CARE IN CANCER
  • 2012-12 Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy in CURRENT COLORECTAL CANCER REPORTS
  • 2012-12 EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis in CANCER AND METASTASIS REVIEWS
  • 2012-09 Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics? in CURRENT COLORECTAL CANCER REPORTS
  • 2012-07 Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2012-06 Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers in ANGIOGENESIS
  • 2011-12 Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer in BMC CANCER
  • 2011-07 Anti-HER agents in gastric cancer: from bench to bedside in NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
  • 2011-05 Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients in BRITISH JOURNAL OF CANCER
  • 2011-04 Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2010-12 Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2010-10 Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan in THE PHARMACOGENOMICS JOURNAL
  • 2010-09 Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? in EPMA JOURNAL
  • 2010-09 Metronomic Chemotherapy for Metastatic Prostate Cancer in DRUGS & AGING
  • 2010-08 Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.5395.a", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.48336.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7841.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.8404.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.440387.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.42505.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419546.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.29980.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417287.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416020.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9024.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415103.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9657.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413179.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.12711.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.488566.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7605.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.24704.35", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415079.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410345.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7010.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.460094.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4527.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.144189.1", 
            "type": "Organization"
          }
        ], 
        "familyName": "Falcone", 
        "givenName": "Alfredo", 
        "id": "sg:person.01006230145.44", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0001-5840-2529"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006230145.44", 
          "https://orcid.org/0000-0001-5840-2529"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:17", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_961.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01006230145.44'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01006230145.44'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01006230145.44'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01006230145.44'


     

    This table displays all metadata directly associated to this object as RDF triples.

    69 TRIPLES      11 PREDICATES      37 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01006230145.44 schema:affiliation N070e79894f9844508303692fdd0689a2
    2 https://www.grid.ac/institutes/grid.12711.34
    3 https://www.grid.ac/institutes/grid.144189.1
    4 https://www.grid.ac/institutes/grid.16872.3a
    5 https://www.grid.ac/institutes/grid.24704.35
    6 https://www.grid.ac/institutes/grid.29980.3a
    7 https://www.grid.ac/institutes/grid.410345.7
    8 https://www.grid.ac/institutes/grid.413179.9
    9 https://www.grid.ac/institutes/grid.415079.e
    10 https://www.grid.ac/institutes/grid.415103.2
    11 https://www.grid.ac/institutes/grid.416020.1
    12 https://www.grid.ac/institutes/grid.417287.f
    13 https://www.grid.ac/institutes/grid.419546.b
    14 https://www.grid.ac/institutes/grid.42505.36
    15 https://www.grid.ac/institutes/grid.440387.c
    16 https://www.grid.ac/institutes/grid.4527.4
    17 https://www.grid.ac/institutes/grid.460094.f
    18 https://www.grid.ac/institutes/grid.48336.3a
    19 https://www.grid.ac/institutes/grid.488566.1
    20 https://www.grid.ac/institutes/grid.7010.6
    21 https://www.grid.ac/institutes/grid.7605.4
    22 https://www.grid.ac/institutes/grid.7841.a
    23 https://www.grid.ac/institutes/grid.8404.8
    24 https://www.grid.ac/institutes/grid.9024.f
    25 https://www.grid.ac/institutes/grid.9657.d
    26 schema:familyName Falcone
    27 schema:givenName Alfredo
    28 schema:identifier N152ff554b55b425e9dd6bb60d8b91c78
    29 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006230145.44
    30 https://orcid.org/0000-0001-5840-2529
    31 schema:sdDatePublished 2019-03-07T15:17
    32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    33 schema:sdPublisher N7622c0bb1b5b409aa7fb39f845a399b3
    34 sgo:license sg:explorer/license/
    35 sgo:sdDataset persons
    36 rdf:type schema:Person
    37 N070e79894f9844508303692fdd0689a2 schema:affiliation https://www.grid.ac/institutes/grid.5395.a
    38 sgo:isCurrent true
    39 rdf:type schema:OrganizationRole
    40 N152ff554b55b425e9dd6bb60d8b91c78 schema:name orcid_id
    41 schema:value 0000-0001-5840-2529
    42 rdf:type schema:PropertyValue
    43 N7622c0bb1b5b409aa7fb39f845a399b3 schema:name Springer Nature - SN SciGraph project
    44 rdf:type schema:Organization
    45 https://www.grid.ac/institutes/grid.12711.34 schema:Organization
    46 https://www.grid.ac/institutes/grid.144189.1 schema:Organization
    47 https://www.grid.ac/institutes/grid.16872.3a schema:Organization
    48 https://www.grid.ac/institutes/grid.24704.35 schema:Organization
    49 https://www.grid.ac/institutes/grid.29980.3a schema:Organization
    50 https://www.grid.ac/institutes/grid.410345.7 schema:Organization
    51 https://www.grid.ac/institutes/grid.413179.9 schema:Organization
    52 https://www.grid.ac/institutes/grid.415079.e schema:Organization
    53 https://www.grid.ac/institutes/grid.415103.2 schema:Organization
    54 https://www.grid.ac/institutes/grid.416020.1 schema:Organization
    55 https://www.grid.ac/institutes/grid.417287.f schema:Organization
    56 https://www.grid.ac/institutes/grid.419546.b schema:Organization
    57 https://www.grid.ac/institutes/grid.42505.36 schema:Organization
    58 https://www.grid.ac/institutes/grid.440387.c schema:Organization
    59 https://www.grid.ac/institutes/grid.4527.4 schema:Organization
    60 https://www.grid.ac/institutes/grid.460094.f schema:Organization
    61 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
    62 https://www.grid.ac/institutes/grid.488566.1 schema:Organization
    63 https://www.grid.ac/institutes/grid.5395.a schema:Organization
    64 https://www.grid.ac/institutes/grid.7010.6 schema:Organization
    65 https://www.grid.ac/institutes/grid.7605.4 schema:Organization
    66 https://www.grid.ac/institutes/grid.7841.a schema:Organization
    67 https://www.grid.ac/institutes/grid.8404.8 schema:Organization
    68 https://www.grid.ac/institutes/grid.9024.f schema:Organization
    69 https://www.grid.ac/institutes/grid.9657.d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...